Antioxidant supplementation improves platelet membrane fluidity in idiopathic retinal periphlebitis (Eales' disease)

Sex-specific relationship between blood selenium levels and platelet count in a large cohort representative of the United States population

While several small studies have found that selenium deficiency is associated with low platelet counts, they lack generalizability. We used data from the National Health and Nutrition Examination Surveys collected over a 12-year period. We examined the relationship between selenium quartiles and platelet count using survey-weighted linear regression models adjusting for age, sex, race, household income to poverty threshold income, highest education attainment, smoking status, red blood cell folate, and body mass index. Of the 21,764 participants, 51% were females, 23% African Americans, and 25% were >65 years of age. Mean (SD) platelet count was 243(64) 10⁹/L and selenium was 183(32) µg/L. Women had significantly higher platelet count but lower selenium levels than men (258 vs. 227 10⁹/L and 181 vs. 185 µg/L respectively; both P < 0.0001). In adjusted analysis, participants in the highest selenium quartile had 8.0x10⁹/L higher platelet count as compared to those in the lowest selenium quartile (95%CI = 4.1 to 11.9; P < 0.0001). Gender modified the relationship between the two; although there was no difference in women, platelet count was higher in the highest than the lowest selenium quartile in men (interaction p-value = 0.001). These findings highlight the importance of selenium and gender in platelet biology which needs to be explored.

The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study

Objectives: To evaluate the effect of ubiquinone and combined antioxidant therapy on mitochondrial function in non-proliferative diabetic retinopathy (NPDR) in a randomized, double-blind, phase IIa, placebo-controlled, clinical trial. Three groups of 20 patients were formed: Group 1, ubiquinone; Group 2, combined therapy; and Group 3, placebo (one daily dose for 6 months).

Methods: Fluidity of the submitochondrial membrane in platelets was determined by examining intensity of fluorescence between the monomer (I_m) and excimer (I_e). Hydrolytic activity of the mitochondrial F₀F₁-ATPase was evaluated with the spectrophotometric method.

Results: Normal, baseline submitochondrial membrane fluidity, 0.24 ± 0.01 I_e/I_m, was significantly diminished in the three study groups vs. normal values (P < 0.0001); placebo, 0.14 ± 0.01 I_e/I_m; ubiquinone, 0.14 ± 0.01 I_e/I_m; and combined therapy, 0.13 ± 0.00 I_e/I_m. Afterward, it increased significantly (P < 0.0001), the ubiquinone group 0.22 ± 0.01 I_e/I_m, combined therapy group, 0.19 ± 0.01 I_e/I_m; with no changes the placebo group. Baseline hydrolytic activity of the F₀F₁-ATPase enzyme increased in the three study groups vs. normal values (184.50 ± 7.84 nmol PO₄), placebo, 304.12 ± 22.83 nmol PO₄ (P < 0.002); ubiquinone, 312.41 ± 25.63 nmol PO₄ (P < 0.009); and combined therapy, 371.28 ± 33.50 nmol PO₄ (P < 0.002). Afterward, a significant decrease the enzymatic activity: ubiquinone, 213.25 ± 14.19 nmol PO₄ (P < 0.001); and combined therapy, 225.55 ± 14.48 nmol PO₄ (P < 0.0001).

Discussion: Mitochondrial dysfunction significantly improved in groups of NPDR patients treated with antioxidants.

An Evidence-Based Systematic Review of Lutein by the Natural Standard Research Collaboration

An evidence-based systematic review of lutein by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.

The modified action of triphenyllead chloride on UVB-induced effects in albumin and lipids

Previously we have shown a toxic effect of the organometallic compound triphenyllead (TPhPb) on cells. In the present study we evaluated the destructive effect of TPhPb on model systems--serum albumin and liposome membranes--alone and under UVB irradiation. UVB irradiation of bovine serum albumin results in protein S-S bond reduction, free SH- and CO- group formation and decrease in fluorescence intensity of tryptophans. Triphenyllead chloride alone and under UVB irradiation did not induce protein oxidation, measured as formation of carbonyl groups, in serum albumin; however, it decreased the content of SH- groups in both cases (alone and under UVB radiation) in a dose-dependent manner. It was found that triphenyllead chloride alone did not induce lipid peroxidation of liposomes but increased their fluidity. However, under UVB irradiation TPhPb dramatically enhances the pro-oxidant action of UVB in a manner dependent on concentration and intensity of radiation, and these effects were suppressed by Trolox. These results suggest that the toxicity of TPhPb under UVB irradiation is due to formation of radical forms of the compound and its disordered effects on the membrane structure.

Eales' disease - current concepts in diagnosis and management

Eales' disease, first described by the British ophthalmologist Henry Eales in 1880, is characterized by three overlapping stages of venous inflammation (vasculitis), occlusion, and retinal neovascularization. Diagnosis is mostly clinical and requires exclusion of other systemic or ocular conditions that could present with similar retinal features. In recent years, immunological, molecular biological, and biochemical studies have indicated the role of human leukocyte antigen, retinal autoimmunity, Mycobacterium tuberculosis genome, and free radical-mediated damage in the etiopathogenesis of this disease. However, its etiology appears to be multifactorial. The management depends on the stage of the disease and consists of medical treatment with oral corticosteroids in the active inflammatory stage and laser photocoagulation in the advanced retinal ischemia and neovascularization stages.